中文

云南白药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-30
ItemAmountY/Y
Revenue¥11.60B+7.0%
Gross profit¥3.55B
Operating income¥2.36B
Net income¥2.03B+5.3%
Gross margin30.6%Net margin 17.5%
Revenue Q/Q+10.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥8.05B69.4%
R&D¥0.08B0.7%
SG&A¥1.28B11.0%
Tax & other¥0.33B2.9%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

泸州老窖古井贡酒中油资本长安汽车铜陵有色格力电器中钨高新中信特钢京东方A中航西飞广发证券盐湖股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies